New European urticaria guideline. What’s new?



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urticaria is a disease which symptoms are caused by the activation and degranulation of the mast cells (MC). Urticaria and angioedema persisting for more than 6 weeks is concerning to be the chronic form of the disease (CU). Chronic spontaneous urticaria (CSU) is the most common subtype of CU and has a great negative impact on all aspects of the patient’s life, causing a decreasing a quality of life, as a burden for a health system and society as a whole. In the present version of the conciliatory document diagnostic approaches in CSU have three goals: to make a differential diagnosis; to evaluate an activity of the disease, its control and the impact on the patient’s life; to identify the triggers of exacerbation or, if possible, the causes of a disease. A basic assessment of disease activity (UAS, AAS), quality of life (CU-Q2oL, AE-QoL) and disease activity control (UCT) are necessary for decisionmaking in the treatment of patients with CSU, better understanding of the disease burden, and documentation improvement and standardization. The aim of a treatment of patients with CSU is the complete control of the symptoms. A therapy should be performed by steps. On the first step a 2nd generation of Hj-antihistamines in standard doses has to be applied. In case of unresponsiveness a dose step-up up to 4 times is recommended, at the third step omalizumab is advised, at the fourth step (inefficiency of omalizumab) - cyclosporine. At any step, it is possible to use a short term course of glucocorticosteroids to set back an exacerbation.

Full Text

Restricted Access

About the authors

I V Danilycheva

NRC Institute ofImmunology FMBA ofRussia

References

  1. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M et al. IgE mediated autoallergy against thyroid peroxidase - a novel pathomechanism of chronic spontaneous urticaria? PloS one. 2011;6:e14794.
  2. Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;pii:S0091-6749(17)31875-4.
  3. Maurer M, Zuberbier T, Siebenhaar F, Krause K. Chronic urticaria - What does the new guideline tell us? J Dtsch Dermatol Ges. 2018;16(5):584-593. doi: 10.1111/ddg.13531.
  4. Zuberbier T, Aberer W, Asero R, Abdul Latiff aH, Baker D, Ballmer-Weber B et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
  5. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317-330.
  6. Magerl M, Borzova E, Giménez-Arnau A, Lawlor F, Mathelier-Fusade P, Metz M et al. The definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA2LEN/ EDF/UNEV consensus panel recommendations. Allergy. 2009;64:1715-1721.
  7. Grattan C. The urticarias: pathophysiology and management. Clin Med. 2012;12:164-167.
  8. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res. 2017:9:438-445.
  9. Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk M, Bérard Fet al. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy. 2015;5:29.
  10. Weller K, Grattan C, Abuzakouk M. Patient profile from the first international burden of illness study in inadequately controlled chronic spontaneous urticaria: ASSURE-CSU. Presented at the European Academy of Dermatology and Venereology (EADV), Copenhagen, Denmark. 7-10 October 2015 (Latebreaker ePoster LATCoP-0036).
  11. Weller K, Schoepke N, Krause K, Ardelean E, Brautigam M, Maurer M. Selected urticaria patients benefit from a referral to tertiary care centres-results of an expert survey. J Eur Acad Dermatol Venereol. 2013;27:e8-16.
  12. Weller K, Viehmann K, Brautigam M. Management of chronic spontaneous urticaria in real life - in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27:43-50.
  13. Maurer M. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought-first results of the multicenter real&life AWARE study. Clinical & Experimental Allergy 47.5 (2017): 684-692.
  14. O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201.
  15. Kang MJ, Kim hS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality-of-life in Korean patients. Ann Dermatol. 2009;21:226-229.
  16. Engin B, Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2008;22:481-486.
  17. Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161(3):197-204.
  18. Maurer M, Altrichter S, Bieber T Biedermann T Bräutigam M, Seyfried S et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202-209.
  19. Saini S, Rosen KE, Hsieh HJL. A randomized, placebocontrolled, dose-ranging study of single dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-573.
  20. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132.
  21. Maurer M, Rosen K, Hsieh HJ et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
  22. Saini SS, Bindslev-Jensen C, Maurer M, Saini S, Grattan C, Gimenéz-Arnau A et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75.
  23. Labrador-Horrillo M, Valero A, Velasco M, Jauregui I, Sastre J, Bartra J et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13:1225-1228. doi: 10.1517/14712598.2013.822484.
  24. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57-62.
  25. Zuberbier T, Maurer M. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol. 2015;11:171-180.
  26. Sussman G. Omalizumab Retreatment of Patients with Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/ CSU) Following Return of Symptoms: Primary Results of the OPTIMA StudyKi/SKIN The Journal of Cutaneous Medicine. 2017;1(3):1-s127.
  27. Maurer M, Kaplan A, Rosén K, Holden M, Iqbal A, Trzaskoma BL et al. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology. 2017. In press.
  28. Sussman G, Hebert J, Gulliver W, Lynde C, Waserman S, Kanani A et al. Insights and advances in chronic urticaria: a Canadian perspective. Allergy Asthma Clin Immunol. 2015;11(1):7.
  29. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-887.
  30. Ohanyan T, Schoepke N, Bolukbasi B, Metz M, Hawro T, Zuberbier T et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol. 2017;140:1710-1713. e11.
  31. Weller K, Groffik A, Church MK. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365-1372. e6.
  32. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64(9):1256-1268.
  33. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68(1):27-36.
  34. Magerl M, Altrichter S, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/ GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802. For details on provocation and threshold testing.
  35. Conlon NP, Edgar JD. Adherence to best practice guidelines in chronic spontaneous urticaria (CSU) improves patient outcome. Eur J Dermatol. 2014;24:385-386.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies